Cas:252004-30-1 Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate manufacturer & supplier

Chemical Name:Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate

CAS.NO:252004-30-1

Synonyms:Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate

Molecular Formula:C₁₁H₉N₃O₄S

Molecular Weight:279.27200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:142.78000

Exact Mass:279.03100

LogP:2.33180

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate Use and application,Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate technical grade,usp/ep/jp grade.

Related News: ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate manufacturer Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate supplier Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate vendor It found that about 5% of both groups of women have a genetic mutation that increases the risk of breast cancer. Phenyl (4-carbamoyl-3-oxo-2,3-dihydro-1,2-thiazol-5-yl)carbamate factory Many branded versions of drugs are currently more expensive in China than in other major markets. They could now be subjected to a centralized procurement program where manufacturers will have to go through a bidding process to get the right to supply drugs to public hospitals, the National Health Commission said in a document published on late Friday.